Welcome to touchPODCAST where you can listen and learn from our expert faculty, hand-picked from the Touch Medical Media family of independent medical websites. Educating physicians on a fully global scale since 2005! We make positive changes to clinical practice, with the ultimate objective of improving patient and community health. Working alongside leading medical experts, societies and industry, our mission is to provide practical, expert opinions to support best practices for busy Healthcare Professionals globally, by translating published data into easily digestible and timely updates Home of: - touchONCOLOGY - touchENDOCRINOLOGY - touchOPHTHALMOLOGY - touchNEUROLOGY - touchCARDIOLOGY - touchINFECTIOUSDISEASES - touchIMMUNOLOGY - touchRESPIRATORY - touchHAEMATOLOGY - touchDERMATOLOGY This information is intended for use by licensed Healthcare Professionals (HCPs). It should not be considered medical advice, diagnosis, or treatment recommendations.
Episodes
Monday Nov 29, 2021
Monday Nov 29, 2021
touchMDT for touchONCOLOGY
Listen to a multidisciplinary tumour board consider the potential of systemic therapy in hepatocellular carcinoma during the current immunotherapy era.
The multidisciplinary team
- Medical oncologist: Prof. Ahmed Kaseb, USA
- Radiation oncologist: Prof. Jinsil Seong, Korea
- Hepatologist: Prof. Peter Galle, Germany
- Surgical oncologist: Dr Michael Choti, USA
This touchPODCAST is for HCPs only.
This activity is funded by an unrestricted independent medical education grant from AstraZeneca. This activity is jointly provided by USF Health and touchIME.
For further information visit our website: https://touchoncologyime.org/patient-care-in-HCC/
Monday Nov 29, 2021
Monday Nov 29, 2021
touchMDT for touchONCOLOGY
Listen to a multidisciplinary tumour board discuss how recent developments are enabling the management of patients with hepatocellular carcinoma to become increasingly individualized.
The multidisciplinary team
- Medical oncologist: Prof. Ahmed Kaseb, USA
- Radiation oncologist: Prof. Jinsil Seong, Korea
- Hepatologist: Prof. Peter Galle, Germany
- Surgical oncologist: Dr Michael Choti, USA
This touchPODCAST is for HCPs only.
This activity is funded by an independent medical education grant from AstraZeneca. This activity is jointly provided by USF Health and touchIME.
For further information visit our website: https://touchoncologyime.org/patient-care-in-HCC/
Monday Nov 29, 2021
Monday Nov 29, 2021
touchMDT for touchONCOLOGY
Listen to a multidisciplinary tumour board share their perspectives on a best practice multidisciplinary approach to patient care in the management of hepatocellular carcinoma.
The multidisciplinary team
- Medical oncologist: Prof. Ahmed Kaseb, USA
- Radiation oncologist: Prof. Jinsil Seong, Korea
- Hepatologist: Prof. Peter Galle, Germany
- Surgical oncologist: Dr Michael Choti, USA
This touchPODCAST is for HCPs only.
This activity is funded by an unrestricted independent medical education grant from AstraZeneca. This activity is jointly provided by USF Health and touchIME.
For further information visit our website: https://touchoncologyime.org/patient-care-in-HCC/
Thursday Nov 25, 2021
Thursday Nov 25, 2021
touchEXPERT OPINIONS for touchOPHTHALMOLOGY
Listen to expert insights on how novel IOLs can address patients’ visual needs, the factors that influence IOL selection and managing patient expectations.
The expert
- Dr Rosa Braga-Mele - Professor of Ophthalmology, Faculty of Medicine at the University of Toronto, Canada.
This touchPODCAST is for HCPs only.
This activity is funded by an unrestricted independent medical education grant from Alcon Laboratories Inc. This activity is jointly provided by USF Health and touchIME.
For further information visit our website: https://touchophthalmologyime.org/balancing-risks-and-benefits-of-intraocular-lens-options-for-cataract-surgery/
Wednesday Nov 10, 2021
Wednesday Nov 10, 2021
touchPANEL DISCUSSION for touchONCOLOGY
Listen as leading experts discuss the latest clinical data for emerging HER2-directed therapies and review novel therapeutic strategies and consider the implications for clinical practice.
The experts
- Dr Laura Biganzoli – Department of Oncology, Hospital of Prato, Prato, Italy
- Dr Peter Fasching – Comprehensive Cancer Center, Erlangen-EMN, Friedrich-Alexander University Erlangen-Nuremberg, Erlangen, Germany
- Dr Sonia Pernas – Catalan Institute of Oncology, and Faculty of Medicine, University of Barcelona, Barcelona, Spain
This touchPODCAST is for HCPs only.
This activity is funded by an unrestricted independent educational grant from SeaGen. This activity is jointly provided by USF Health and touchIME.
For further information visit our website: https://touchoncologyime.org/expanding_options_her2_advanced_breast_cancer/
Wednesday Nov 10, 2021
Wednesday Nov 10, 2021
touchMDT for touchONCOLOGY
Listen to a medical oncologist, a pathologist, a radiation oncologist and an oncology nurse practitioner discuss how to optimize treatment decisions, taking into account emerging therapies as well as patient expectations and preferences.
The multidisciplinary team
- Medical oncologist: Dr Alexander Drilon, USA
- Pathologist: Prof. Keith Kerr, UK
- Radiation oncologist: Prof. Andrea Bezjak, Canada
- Oncology nurse practitioner: Dr Marianne Davies, USA
This touchPODCAST is for HCPs only.
This activity is funded by an unrestricted independent medical education grant from Merck & Co Ltd, Turning Point Therapeutics, Regeneron Pharmaceuticals, Inc. and Sanofi Genzyme. This activity is jointly provided by USF Health and touchIME.
For further information visit our website: https://touchoncologyime.org/mdt-navigating-diagnosis-and-treatment-nsclc/
Wednesday Nov 10, 2021
Wednesday Nov 10, 2021
touchMDT for touchONCOLOGY
Listen to a medical oncologist and a pathologist discuss the evolving role of biomarker testing in NSCLC in the light of emerging testing methodologies and treatment targets.
The multidisciplinary team
- Medical oncologist: Dr Alexander Drilon, USA
- Pathologist: Prof. Keith Kerr, UK
This touchPODCAST is for HCPs only.
This activity is funded by an unrestricted independent medical education grant from Merck & Co Ltd, Turning Point Therapeutics, Regeneron Pharmaceuticals, Inc. and Sanofi Genzyme. This activity is jointly provided by USF Health and touchIME.
For further information visit our website: https://touchoncologyime.org/mdt-navigating-diagnosis-and-treatment-nsclc/
Wednesday Nov 10, 2021
Wednesday Nov 10, 2021
Listen to a medical oncologist, a pathologist and an oncology nurse practitioner discuss the evolving treatment landscape and how treatment decisions need to take into account potential side effects.
The multidisciplinary team
- Medical oncologist: Dr Alexander Drilon, USA
- Pathologist: Prof. Keith Kerr, UK
- Oncology nurse practitioner: Dr Marianne Davies, USA
This touchPODCAST is for HCPs only.
This activity is funded by an independent medical education grant from Merck & Co Ltd, Turning Point Therapeutics, Regeneron Pharmaceuticals, Inc. and Sanofi Genzyme. This activity is jointly provided by USF Health and touchIME.
For further information visit our website: https://touchoncologyime.org/mdt-navigating-diagnosis-and-treatment-nsclc/
Wednesday Nov 10, 2021
Wednesday Nov 10, 2021
touchMDT for touchONCOLOGY
Listen to a medical oncologist and a radiation oncologist discuss the importance of the initial assessment in NSCLC and the role of the different members of the multidisciplinary team.
The multidisciplinary team
- Medical oncologist: Dr Alexander Drilon, USA
- Radiation oncologist: Prof. Andrea Bejzak, Canada
This touchPODCAST is for HCPs only.
This activity is funded by an unrestricted independent medical education grant from Merck & Co Ltd, Turning Point Therapeutics, Regeneron Pharmaceuticals, Inc. and Sanofi Genzyme. This activity is jointly provided by USF Health and touchIME.
For further information visit our website: https://touchoncologyime.org/mdt-navigating-diagnosis-and-treatment-nsclc/
Friday Nov 05, 2021
Friday Nov 05, 2021
touchPANEL DISCUSSION for touchONCOLOGY
Listen to leading experts review the latest advances in HR+ breast cancer, focusing on the management of specific patient subgroups and the potential impact of emerging oral, second-generation SERDs on patient standard of care.
The experts
- Prof. Hope S Rugo – UCSF Comprehensive Cancer Center, San Francisco, CA, USA
- Dr Fatima Cardoso – Champalimaud Clinical Center, Lisbon, Portugal
- Dr Matti Aapro – Genolier Cancer Center, Genolier, Switzerland
This touchPODCAST is for HCPs only.
This activity is funded by an unrestricted independent educational grant from Sanofi Genzyme. This activity is provided by touchIME.
For further information visit our website: https://touchoncologyime.org/emerging-serds-for-treating-hr-positive-breast-cancer/